MS4A15 gene expression as a prognostic marker for clinical outcomes in lung adenocarcinoma
Overall, <i>MS4A15</i> emerged as a promising prognostic biomarker for LUAD and could serve as a potential target for the development of novel therapeutic interventions.
Authors
- Satoshi Watanabe (ORCID: https://orcid.org/0000-0003-0041-6981)
- Bin Qing
- Ninh M. La‐Beck (ORCID: https://orcid.org/0000-0002-1956-3263)
- Xinye Zhang (ORCID: https://orcid.org/0000-0002-2421-3129)
- Tracy L. Leong (ORCID: https://orcid.org/0000-0002-1950-1505)
- Lingxiao Qiu (ORCID: https://orcid.org/0000-0002-1703-0797)
- Chuangye Wang (ORCID: https://orcid.org/0000-0001-5965-9377)
- Tingcheng Li (ORCID: https://orcid.org/0000-0001-8304-8699)
- Armida D’Incecco
- Gang Liu (ORCID: https://orcid.org/0000-0001-9270-6796)
- Jincheng Liu
- Xueping Liu (ORCID: https://orcid.org/0000-0002-7978-5028)
- Zhi Ping Xu (ORCID: https://orcid.org/0000-0001-6070-5035)
- Qi Li (ORCID: https://orcid.org/0000-0001-5938-0173)
- Chen Zhao (ORCID: https://orcid.org/0000-0003-3213-2852)
- Li Bai (ORCID: https://orcid.org/0000-0002-6283-986X)
Institutions
- Texas Tech University (US)
- University of Teramo (IT)
- Army Medical University (CN)
- Austin Hospital (AU)
- Nini Hospital (LB)
- First Affiliated Hospital of Zhengzhou University (CN)
- Niigata University (JP)
- Texas Tech University Health Sciences Center (US)
- Nanjing University of Aeronautics and Astronautics (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2024-12-24
- DOI
- https://doi.org/10.21037/tlcr-24-623
- Citations
- 1
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Chongqing Science and Technology Commission
- Army Medical University